Positive interim Alpha DaRT data from multiple clinical trials in pancreatic cancer, a combination study with pembrolizumab in patients with recurrent unresectable or metastatic HNSCC, and other clinical trials announced February 4, 2025
ASCO GI 2025: Positive Updated Data from ASPEN-06 Ph 2 Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer presented January 28, 2025
FAILED TRIAL: Ph 3 LEAP-015 Trial of KEYTRUDA, LENVIMA, Chemo combo in Patients with HER2-neg Gastroesophageal Adenocarcinoma did not meet co-primary endpoint of OS January 28, 2025
ASCO GI 2025: Encouraging Results from Ph 1b/2 STELLAR-001 Trial of Zanzalintinib +/- Immune Checkpoint Inhibitor in Metastatic CRC announced January 28, 2025
ASCO GI 2025: Results from CheckMate -8HW Analysis of Opdivo + Yervoy Compared to Opdivo Monotherapy in Patients with MSI-H or MMRD Metastatic CRC announced January 28, 2025
ASCO GI 2025: Latest Ph 1/2 Data on ATN-022 in Advanced/Metastatic Gastric Cancer Including an ORR of 42.9% presented January 28, 2025
ASCO GI 2025: Final Ph 2 Clinical Casdozokitug Combination Data in Patients with Metastatic HCC Presented January 28, 2025
ASCO GI 2025: Initial Ph 2 Data for Vilastobart (XTX101) in Combination with Atezolizumab in Patients with MSS CRC announced January 28, 2025
ASCO GI 2025: Preliminary Cohort A Data from Ph 2 ASCEND Trial of Certepetide with SOC Chemo in Metastatic Pancreatic Ductal Adenocarcinoma reported January 28, 2025
ASCO GI 2025: Results from Subgroup Analysis of Ph 3 CABINET Pivotal Study of Cabozantinib in Advanced Gastrointestinal NET announced January 28, 2025
ASCO GI 2025: Results from Ph 3 CALGB (Alliance) / SWOG 80702 Clinical Trial in CRC announced January 28, 2025
ASCO GI 2025: BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic CRC from the Ph 3 BREAKWATER trial January 28, 2025
FDA Approves Lumakras® (Sotorasib) + Vectibix® (Panitumumab) For Chemorefractory KRAS G12C-Mutated Metastatic CRC January 21, 2025
Positive Update provided on Ph 2a Arm of IMM-1-104 in Combination with Modified FOLFIRINOX for 1L Pancreatic Cancer January 15, 2025
Invikafusp Alfa (STAR0602) Receives US FDA Fast Track Designation for Treatment of Unresectable, Locally Advanced, or Metastatic TMB-H CRC January 15, 2025
Supplemental NDA for cabozantinib in pNET and epNET patients no longer the subject of discussion at an ODAC meeting January 15, 2025
ELC-100 receives Orphan Drug Designation in the U.S. for the treatment of pancreatic neuroendocrine tumors January 15, 2025
China’s NMPA Approves VYLOYTM (zolbetuximab) for 1L Treatment of Advanced Gastric or GEJ Adenocarcinoma January 7, 2025
TEVIMBRA Approved in US for 1L Treatment of Gastric and GEJ Cancers in Combination with Chemotherapy December 31, 2024
EC approves Opdivo + Yervoy for the 1L Treatment of Adult Patients with MSI-H or dMMR Metastatic CRC December 31, 2024
Positive Interim Ph 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer Announced December 26, 2024
